8.635  -0.086 (-0.99%)		07-18 16:00
Open: 8.8 High: 8.9 Volume: 67,618		Pre. Close: 8.721 Low: 8.605 Market Cap: 42(M)

Short term
Mid term
Targets	6-month :	10.58	1-year :	12.35
Resists	First :	9.06	Second :	10.58
Pivot price	8.69
Supports	First :	8.41	Second :	8.02
MAs	MA(5) :	8.68	MA(20) :	8.59
	MA(100) :	8.25	MA(250) :	9.67
MACD	MACD :	0.1	Signal :	0.1
%K %D	K(14,3) :	49.1	D(3) :	51.2
RSI	RSI(14): 53.6
52-week	High :	11.88	Low :	6.8

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ GNOM ] has closed above bottom band by 41.6%. Bollinger Bands are 31.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	8.91 - 8.96	8.96 - 9.01
Low:	8.49 - 8.54	8.54 - 8.59
Close:	8.56 - 8.64	8.64 - 8.72

The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.

Wed, 18 Jun 2025
5 Best ETFs Tracking CRISPR Gene Editing - The Motley Fool

Thu, 30 Jan 2025
Metagenomic global survey and in-depth genomic analyses of Ruminococcus gnavus reveal differences across host lifestyle and health status - Nature

Wed, 29 Jan 2025
Global meta-analysis shows action is needed to halt genetic diversity loss - Nature

Mon, 30 Dec 2024
Genomic analysis of global Plasmodium vivax populations reveals insights into the evolution of drug resistance - Nature

Sat, 02 Nov 2024
Longitudinal genomics reveals carbapenem-resistant Acinetobacter baumannii population changes with emergence of highly resistant ST164 clone - Nature

Fri, 16 Feb 2024
Population Genomic Sequencing Delineates Global Landscape of Copy Number Variations that Drive Domestication and Breed Formation of in Chicken - Frontiers

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Financial Services
Industry: Asset Management - Global
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.